Literature DB >> 3568698

Conditional power calculations as an aid in the decision whether to continue a clinical trial.

P K Andersen.   

Abstract

It is shown how stochastically curtailed testing can be included in the process of deciding whether to continue a clinical trial in which survival times or times to some other event in two treatment arms are compared. A model with constant intensities is used. One examines the power function of the test which would be computed if the trial were prolonged, conditional on the course of the trial up to the time of decision.

Entities:  

Mesh：

Year:  1987        PMID： 3568698     DOI： 10.1016/0197-2456(87)90027-4

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN： 0197-2456


  6 in total

1.  Somatostatin plus isosorbide 5-mononitrate versus somatostatin in the control of acute gastro-oesophageal variceal bleeding: a double blind, randomised, placebo controlled clinical trial.

Authors:  F Junquera; J C López-Talavera; F Mearin; E Saperas; S Videla; J R Armengol; R Esteban; J R Malagelada
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

2.  Can rodent longevity studies be both short and powerful?

Authors:  Henry T Robertson; Daniel L Smith; Nicholas M Pajewski; Richard H Weindruch; Theodore Garland; George Argyropoulos; Alex Bokov; David B Allison
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-11-04       Impact factor: 6.053

3.  Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer.

Authors:  Robert J Myerson; Benjamin Tan; Steven Hunt; Jeffrey Olsen; Elisa Birnbaum; James Fleshman; Feng Gao; Lannis Hall; Ira Kodner; A Craig Lockhart; Matthew Mutch; Michael Naughton; Joel Picus; Caron Rigden; Bashar Safar; Steven Sorscher; Rama Suresh; Andrea Wang-Gillam; Parag Parikh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-15       Impact factor: 7.038

4.  Patient and Provider Preferences for Colorectal Cancer Screening: How Does CT Colonography Compare to Other Modalities?

Authors:  Audrey H Calderwood; Sharmeel K Wasan; Timothy C Heeren; Paul C Schroy
Journal:  Int J Canc Prev       Date:  2011

5.  Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.

Authors:  Joseph O Moore; Stephen L George; Richard K Dodge; Philip C Amrein; Bayard L Powell; Jonathan E Kolitz; Maria R Baer; Frederick R Davey; Clara D Bloomfield; Richard A Larson; Charles A Schiffer
Journal:  Blood       Date:  2004-11-30       Impact factor: 22.113

6.  Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.

Authors:  Katrin Hoffmann; Tom Ganten; Daniel Gotthardtp; Boris Radeleff; Utz Settmacher; Otto Kollmar; Silvio Nadalin; Irini Karapanagiotou-Schenkel; Christof von Kalle; Dirk Jäger; Markus W Büchler; Peter Schemmer
Journal:  BMC Cancer       Date:  2015-05-11       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.